27-Mar-2025 1:00 AM CST - Business Wire Innate Pharma Reports Full Year 2024 Financial Results and Business Update #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release. Our strategy is clear: drive innovation through our ANKET NK-cell engager platform and accelerate our ADC programs. We are making strong clinical progress, with our lead proprietary ANKET, IPH6501 ad
10-Jan-2025 12:00 AM CST - Business Wire Innate Pharma Announces Transformative Strategy to Accelerate Growth #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. "Our updated strategy underscores Innate Pharmas unwavering dedication to innovation, collaboration, and delivering transformative th
20-Dec-2024 12:00 AM CST - Business Wire Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA. Jonathan Dickinson, Chief Executive Officer of Innate Pharma, will represent the Company in a session scheduled Tuesday, January 14, 2025 from 11:15 - 11:55 am PST. Other Executive Boar
13-Nov-2024 12:00 AM CST - Business Wire Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its business update and financial results for the first nine months of 2024. "Im honored to join Innate Pharma at such a pivotal moment in its evolution, said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. We achieved notable regulatory milestones during the quarter including encouraging initial feedback from the FDA for lacutama
27-Mar-2025 1:00 AM CST - Business Wire Innate Pharma Reports Full Year 2024 Financial Results and Business Update #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release. Our strategy is clear: drive innovation through our ANKET NK-cell engager platform and accelerate our ADC programs. We are making strong clinical progress, with our lead proprietary ANKET, IPH6501 ad
10-Jan-2025 12:00 AM CST - Business Wire Innate Pharma Announces Transformative Strategy to Accelerate Growth #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. "Our updated strategy underscores Innate Pharmas unwavering dedication to innovation, collaboration, and delivering transformative th
20-Dec-2024 12:00 AM CST - Business Wire Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA. Jonathan Dickinson, Chief Executive Officer of Innate Pharma, will represent the Company in a session scheduled Tuesday, January 14, 2025 from 11:15 - 11:55 am PST. Other Executive Boar
13-Nov-2024 12:00 AM CST - Business Wire Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its business update and financial results for the first nine months of 2024. "Im honored to join Innate Pharma at such a pivotal moment in its evolution, said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. We achieved notable regulatory milestones during the quarter including encouraging initial feedback from the FDA for lacutama
